Date revised

Education Credit

2.5 CME

Nurses may claim up to 2.5 contact hours for this session.

University of Minnesota approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN JA0000810-9999-19-082-L01-P. Initial Release Date: 12/7/19.

Translational Research Symposium: Advances in Translation for Traumatic Brain Injury (TBI) and Antiepileptogenesis

Convention Center, Room 316
5:30 PM-8:00 PM
Behavioral Health Providers

This symposium focuses on the current state of research on Traumatic Brain Injury (TBI) and Antiepileptogenesis with particular emphasis on the challenges, achievements and possible solutions for translating ideas into therapies. This sesion will provide an overview of the challenges of translating basic findings to clinical utility in this specific domain of epilepsy research with speakers giving up-to-date reviews of the state of knowledge from both animal and clinical studies; a debate format discussion of the utility of animal work in pre-clinical research; an update on EpiBioS4Rx; a discussion of different trial methodologies and collaborative approaches that may be useful in this (and other domains) and, finally, an open panel discussion.

Learning Objectives

Following participation in this activity, participants will be able to:

  • Describe the current state of basic and translational research related to post-TBI epilepsy (PTE)
  • Discuss current and future pathways to develop anti-epileptogenic interventions for PTE
  • Recognize the competing research priorities for PTE



Co-chairs: Terrence O'Brien, MD and Solomon L. Moshé, MD

Introduction, Sydney Cash, MD, PhD
The EpiBioS4Rx Experience and Update, Jerome P. Engel, Jr., MD, PhD
The Perspective of Stakeholders, Daniel Correa, MD
What Have Animal Studies Taught Us so Far?, Asla Pitkanen, MD
What have Human Studies Taught Us so Far? Paul Vespa, MD
Pro and Con: Are Preclinical/Animal Studies Useful for the Translation of Research to Improved Care? Thomas Sutula, MD, PhD and Jacqueline French, MD
Other Ongoing Approaches to Coordinate Pre- and Post-clinical Studies and/or Alternative Clinical Trial Approaches, Zachary Grinspan, MD
Panel Discussion and Conclusions